FDA Says Take Note: Document Supplement GMP Corrections
This article was originally published in The Rose Sheet
Executive Summary
FDA's latest supplement GMP warnings once again demonstrate the importance of appropriate documentation during manufacturing and in responding to questions from agency inspectors.
You may also be interested in...
Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings
Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.
GMP Documentation, Identity Testing Continue To Trip Supplement Firms
Warnings from FDA's Office of Regulatory Affairs make clear that failing to document compliance with each GMP requirement renders those parts of the process noncompliant. Warning letters posted March 22 also include FDA's latest enforcement against firms marketing bulk caffeine.
Rates Up, Guidance Absent: FSMA Re-inspection User Fees On Hold
Without a guidance for requesting fee reductions, FDA will not bill firms for re-inspections of facilities found non-compliant with manufacturing regulations or for costs linked to a firm failing to comply with a recall order.